RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies

NCT05923541 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

6

Enrollment

OTHER_GOV

Sponsor class

Conditions

Hematologic Malignancies

Interventions

DRUG: RD13-02 cell infusion

Sponsor

Henan Cancer Hospital

Collaborators

[object Object]